Focal Segmental Glomerulosclerosis - 27 Studies Found
| Completed |
: A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) : Primary Focal Segmental Glomerulosclerosis : 2012-08-13 :
|
| Completed |
: Sirolimus for Focal Segmental Glomerulosclerosis : Focal Glomerulosclerosis : 2002-06-26 : Drug: Sirolimus |
| Completed |
: Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis :
: 2008-12-02 : Drug: tripterygium wilfordii (TW) Pre 30mg/d +TW 120 mg/d, po for 12 weeks |
| Active, not recruiting |
: Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis :
|
| Completed |
: A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) : Glomerulosclerosis, Focal Segmental : 2013-11-27 : Drug: Losmapimod Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, |
| Completed |
: Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial : Focal Segmental Glomerulosclerosis : 2008-12-22 :
|
| Withdrawn |
: Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 : Focal Segmental Glomerulosclerosis : 2008-12-31 : Drug: Galactose Oral galactose, 0.2 g/kg/dose twice daily for 28 days |
| Completed |
: Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients :
|
| Completed |
: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS : Primary Focal Segmental Glomerulosclerosis : 2012-04-05 : Biological: Rituximab Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 |
| Completed |
: Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis :
|